Farnesyltransferase inhibitor FTI-277 reduces mortality of septic mice along with improved bacterial clearance

Journal of Pharmacology and Experimental Therapeutics

Volumn 339, Issue 3, 2011, Pages 832-841

  Yang, Wen ^a,c   Yamada, Marina ^a,b   Tamura, Yoshiaki ^a,b   Chang, Kyungho ^a   Mao, Ji ^a,b   Zou, Lin ^a   Feng, Yan ^a   Kida, Kotaro ^a   Scherrer Crosbie, Marielle ^a   Chao, Wei ^a   Ichinose, Fumito ^a   Yu, Yong Ming ^a,b   Fischman, Alan J ^b   Tompkins, Ronald G ^a,b   Yao, Shanglong ^c   Kaneki, Masao ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b SHRINERS HOSPITALS FOR CHILDREN   (United States)

^c HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CD28 ANTIBODY; CD3 ANTIBODY; CD4 ANTIGEN; N [[5 [(2 AMINO 3 MERCAPTOPROPYL)AMINO][1,1' BIPHENYL] 2 YL]CARBONYL]METHIONINE METHYL ESTER; PROTEIN FARNESYLTRANSFERASE; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; APOPTOSIS; ARTICLE; BACTERIAL CLEARANCE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG MECHANISM; ENZYME ACTIVITY; IMMUNITY; MACROPHAGE FUNCTION; MALE; MORTALITY; MOUSE; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SEPSIS; SPLEEN; SPLEEN CELL; SURVIVAL; THYMUS;

ANIMALS; BACTERIAL LOAD; CECUM; CYTOKINES; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; FARNESYLTRANSTRANSFERASE; HEART FUNCTION TESTS; HEMODYNAMICS; HMGB1 PROTEIN; LUNG; MALE; METHIONINE; MICE; MICE, INBRED C57BL; PROTEIN PRENYLATION; SEPSIS; SPLEEN; T-LYMPHOCYTES;

EID: 81555195490     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.111.183558     Document Type: Article

References (40)

1. Almog Y, Novack V, Eisinger M, Porath A, Novack L, and Gilutz H (2007) The effect of statin therapy on infection-related mortality in patients with atherosclerotic diseases. Crit Care Med 35:372-378. (Pubitemid 46148524)
2. Almog Y, Shefer A, Novack V, Maimon N, Barski L, Eizinger M, Friger M, Zeller L, and Danon A (2004) Prior statin therapy is associated with a decreased rate of severe sepsis. Circulation 110:880-885. (Pubitemid 39096018)
3. Ayyadurai S, Lepidi H, Nappez C, Raoult D, and Drancourt M (2010) Lovastatin protects against experimental plague in mice. PLoS One 5:e10928.
4. Bommhardt U, Chang KC, Swanson PE, Wagner TH, Tinsley KW, Karl IE, and Hotchkiss RS (2004) Akt decreases lymphocyte apoptosis and improves survival in sepsis. J Immunol 172:7583-7591. (Pubitemid 38747622)
5. Dombrovskiy VY, Martin AA, Sunderram J, and Paz HL (2007) Rapid increase in hospitalization and mortality rates for severe sepsis in the United States: a trend analysis from 1993 to 2003. Crit Care Med 35:1244-1250. (Pubitemid 46642649)
6. Dunn SE, Youssef S, Goldstein MJ, Prod'homme T, Weber MS, Zamvil SS, and Steinman L (2006) Isoprenoids determine Th1/Th2 fate in pathogenic T cells, providing a mechanism of modulation of autoimmunity by atorvastatin. J Exp Med 203:401-412. (Pubitemid 43290849)
7. Fontenot JD, Gavin MA, and Rudensky AY (2003) Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 4:330-336. (Pubitemid 36432314)
8. Francisco LM, Salinas VH, Brown KE, Vanguri VK, Freeman GJ, Kuchroo VK, and Sharpe AH (2009) PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med 206:3015-3029.
9. Gelb MH, Brunsveld L, Hrycyna CA, Michaelis S, Tamanoi F, Van Voorhis WC, and Waldmann H (2006) Therapeutic intervention based on protein prenylation and associated modifications. Nat Chem Biol 2:518-528. (Pubitemid 44413234)
10. Goalstone M, Carel K, Leitner JW, and Draznin B (1997) Insulin stimulates the phosphorylation and activity of farnesyltransferase via the Ras-mitogen-activated protein kinase pathway. Endocrinology 138:5119-5124. (Pubitemid 27509668)
11. Goalstone M, Kamath V, and Kowluru A (2010) Glucose activates prenyltransferases in pancreatic islet beta-cells. Biochem Biophys Res Commun 391:895-898.
12. Guignant C, Lepape A, Huang X, Kherouf H, Denis L, Poitevin F, Malcus C, Chéron A, Allaouchiche B, Gueyffier F, et al. (2011) Programmed death-1 levels correlate with increased mortality, nosocomial infection and immune dysfunctions in septic shock patients. Crit Care 15:R99.
13. Hoogerwerf JJ, Tanck MW, van Zoelen MA, Wittebole X, Laterre PF, and van der Poll T (2010) Soluble ST2 plasma concentrations predict mortality in severe sepsis. Intensive Care Med 36:630-637.
14. Huang X, Venet F, Wang YL, Lepape A, Yuan Z, Chen Y, Swan R, Kherouf H, Monneret G, Chung CS, and***Ayala A (2009) PD-1 expression by macrophages plays a pathologic role in altering microbial clearance and the innate inflammatory response to sepsis. Proc Natl Acad Sci 106:6303-6308.
15. Janda S, Young A, Fitzgerald JM, Etminan M, and Swiston J (2010) The effect of statins on mortality from severe infections and sepsis: a systematic review and meta-analysis. J Crit Care 25:656, e7-e22.
16. Kagami S, Owada T, Kanari H, Saito Y, Suto A, Ikeda K, Hirose K, Watanabe N, Iwamoto I, and Nakajima H (2009) Protein geranylgeranylation regulates the balance between Th17 cells and Foxp3+ regulatory T cells. Int Immunol 21:679-689.
17. Karlsson S, Pettilä V, Tenhunen J, Laru-Sompa R, Hynninen M, and Ruokonen E (2008) HMGB1 as a predictor of organ dysfunction and outcome in patients with severe sepsis. Intensive Care Med 34:1046-1053. (Pubitemid 351903793)
18. Kellum JA, Kong L, Fink MP, Weissfeld LA, Yealy DM, Pinsky MR, Fine J, Krichevsky A, Delude RL, Angus DC, et al. (2007) Understanding the inflammatory cytokine response in pneumonia and sepsis: results of the Genetic and Inflammatory Markers of Sepsis (GenIMS) Study. Arch Intern Med 167:1655-1663. (Pubitemid 47280347)
19. Kumar A, Beresini MH, Dhawan P, and Mehta KD (1996) Alpha-subunit of farnesyltransferase is phosphorylated in vivo: effect of protein phosphatase-1 on enzymatic activity. Biochem Biophys Res Commun 222:445-452. (Pubitemid 26335036)
20. Levy MM, Dellinger RP, Townsend SR, Linde-Zwirble WT, Marshall JC, Bion J, Schorr C, Artigas A, Ramsay G, Beale R, et al. (2010) The Surviving Sepsis Campaign: results of an international guideline-based performance improvement program targeting severe sepsis. Intensive Care Med 36:222-231.
21. Mausner-Fainberg K, Luboshits G, Mor A, Maysel-Auslender S, Rubinstein A, Keren G, and George J (2008) The effect of HMG-CoA reductase inhibitors on naturally occurring CD4+CD25+ T cells. Atherosclerosis 197:829-839. (Pubitemid 351417882)
22. Merx MW, Liehn EA, Graf J, van de Sandt A, Schaltenbrand M, Schrader J, Hanrath P, and Weber C (2005) Statin treatment after onset of sepsis in a murine model improves survival. Circulation 112:117-124. (Pubitemid 40962577)
23. Merx MW, Liehn EA, Janssens U, Lütticken R, Schrader J, Hanrath P, and Weber C (2004) HMG-CoA reductase inhibitor simvastatin profoundly improves survival in a murine model of sepsis. Circulation 109:2560-2565. (Pubitemid 38720557)
24. Minamishima S, Bougaki M, Sips PY, Yu JD, Minamishima YA, Elrod JW, Lefer DJ, Bloch KD, and Ichinose F (2009) Hydrogen sulfide improves survival after cardiac arrest and cardiopulmonary resuscitation via a nitric oxide synthase 3-dependent mechanism in mice. Circulation 120:888-896.
25. Nascimento DC, Alves-Filho JC, Sônego F, Fukada SY, Pereira MS, Benjamim C, Zamboni DS, Silva JS, and Cunha FQ (2010) Role of regulatory T cells in long-term immune dysfunction associated with severe sepsis. Crit Care Med 38:1718-1725.
26. Osuchowski MF, Welch K, Siddiqui J, and Remick DG (2006) Circulating cytokine/inhibitor profiles reshape the understanding of the SIRS/CARS continuum in sepsis and predict mortality. J Immunol 177:1967-1974. (Pubitemid 44092537)
27. Rosch JW, Boyd AR, Hinojosa E, Pestina T, Hu Y, Persons DA, Orihuela CJ, and Tuomanen EI (2010) Statins protect against fulminant pneumococcal infection and cytolysin toxicity in a mouse model of sickle cell disease. J Clin Invest 120:627-635.
28. Shinozaki S, Inoue Y, Yang W, Fukaya M, Carter EA, Ming-Yu Y, Fischman A, Tompkins R, and Kaneki M (2010) Farnesyltransferase inhibitor improved survival following endotoxin challenge in mice. Biochem Biophys Res Commun 391:1459-1464.
29. Stickney JT and Buss JE (2000) Murine guanylate-binding protein: incomplete geranylgeranyl isoprenoid modification of an interferon-gamma- inducible guanosine triphosphate-binding protein. Mol Biol Cell 11:2191-2200. (Pubitemid 30489907)
30. Sugita H, Fujimoto M, Yasukawa T, Shimizu N, Sugita M, Yasuhara S, Martyn JA, and Kaneki M (2005) Inducible nitric-oxide synthase and NO donor induce insulin receptor substrate-1 degradation in skeletal muscle cells. J Biol Chem 280:14203-14211. (Pubitemid 40517322)
31. Sugita M, Sugita H, and Kaneki M (2007) Farnesyltransferase inhibitor, manumycin a, prevents atherosclerosis development and reduces oxidative stress in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 27:1390-1395. (Pubitemid 46809430)
32. Takano K, Yamamoto S, Tomita K, Takashina M, Yokoo H, Matsuda N, Takano Y, and Hattori Y (2011) Successful treatment of acute lung injury with pitavastatin in septic mice: potential role of glucocorticoid receptor expression in alveolar macrophages. J Pharmacol Exp Ther 336:381-390.
33. Thibault HB, Kurtz B, Raher MJ, Shaik RS, Waxman A, Derumeaux G, Halpern EF, Bloch KD, and Scherrer-Crosbie M (2010) Noninvasive assessment of murine pulmonary arterial pressure: validation and application to models of pulmonary hypertension. Circ Cardiovasc Imaging 3:157-163.
34. Tleyjeh IM, Kashour T, Hakim FA, Zimmerman VA, Erwin PJ, Sutton AJ, and Ibrahim T (2009) Statins for the prevention and treatment of infections: a systematic review and meta-analysis. Arch Intern Med 169:1658-1667.
35. Tournoux F, Petersen B, Thibault H, Zou L, Raher MJ, Kurtz B, Halpern EF, Chaput M, Chao W, Picard MH, et al. (2011) Validation of noninvasive measurements of cardiac output in mice using echocardiography. J Am Soc Echocardiogr 24:465-470.
36. Xue X, Lai KT, Huang JF, Gu Y, Karlsson L, and Fourie A (2006) Anti-inflammatory activity in vitro and in vivo of the protein farnesyltransferase inhibitor tipifarnib. J Pharmacol Exp Ther 317:53-60.
37. Yamada M, Kida K, Amutuhaire W, Ichinose F, and Kaneki M (2010) Gene disruption of caspase-3 prevents MPTP-induced Parkinson's disease in mice. Biochem Biophys Res Commun 402:312-318.
38. Yang H, Ochani M, Li J, Qiang X, Tanovic M, Harris HE, Susarla SM, Ulloa L, Wang H, DiRaimo R, et al. (2004) Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc Natl Acad Sci USA 101:296-301. (Pubitemid 38084244)
39. Yasuda H, Yuen PS, Hu X, Zhou H, and Star RA (2006) Simvastatin improves sepsis-induced mortality and acute kidney injury via renal vascular effects. Kidney Int 69:1535-1542.
40. Youssef S, Stüve O, Patarroyo JC, Ruiz PJ, Radosevich JL, Hur EM, Bravo M, Mitchell DJ, Sobel RA, Steinman L, et al. (2002) The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 420:78-84. (Pubitemid 35291443)